Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04920786 · ClinicalTrials.gov registry record · Phase 1
Sequential Dose-escalation Study to Assess the Safety, Tolerability and Pharmacokinetics of TB006 in Healthy Subjects
A Phase 1 study, sponsored by TrueBinding.
- Completed
- Registry status
- Phase 1
- Development phase
- 48
- Enrollment target
NCT04920786 is a Phase 1 study that has completed, run by TrueBinding. The registered enrollment target is 48 participants.
The verdict
NCT04920786, a Phase 1 study, has completed, sponsored by TrueBinding.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 48 participants
- Enrollment target
Study Summary
This is a single dose, dose-escalation study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of TB006, a monoclonal antibody that will be studied as a disease modifying treatment for Alzheimer's disease.
Interventions
- DRUG TB006
- OTHER Sterile saline (Placebo)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2021-06-01 |
| Est. Completion | 2022-05-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04920786
The ClinicalTrials.gov registry entry for NCT04920786 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is TrueBinding, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which TB006 is the first listed.
NCT04920786 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04920786 about?
NCT04920786 is a clinical study titled "Sequential Dose-escalation Study to Assess the Safety, Tolerability and Pharmacokinetics of TB006 in Healthy Subjects". This is a single dose, dose-escalation study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of TB006, a monoclonal antibody that will be studied as a disease modifying treatment for Alzheimer's disease.
What is the current status of trial NCT04920786?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 48 participants. The study started on 2021-06-01. Estimated completion is 2022-05-03.
What interventions are being tested in trial NCT04920786?
The interventions under investigation include: TB006 (DRUG), Sterile saline (Placebo) (OTHER).
Who is sponsoring clinical trial NCT04920786?
This trial is sponsored by TrueBinding, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.